The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.